Researcher
Séverine Vermeire
- Disciplines:Endocrinology and metabolic diseases, Gastro-enterology and hepatology, Biomarker discovery and evaluation, Drug discovery and development, Medicinal products, Pharmaceutics, Pharmacognosy and phytochemistry, Pharmacology, Pharmacotherapy, Toxicology and toxinology, Other pharmaceutical sciences
Affiliations
- Translational Research in GastroIntestinal Disorders (Division)
Member
From1 Oct 1999 → Today
Projects
1 - 10 of 63
- Development of new strategies for value-based care in chronic inflammatory bowel diseases.From5 Dec 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Gut functional and inflammatory disorders: biomarker and therapeutic target discovery (GUT-FIRE)From10 Jul 2023 → TodayFunding: IOF - mandates
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom1 Apr 2023 → TodayFunding: HORIZON.2.1 - Health
- Development, Validation, and Valorization of a Patient Preference Platform to Inform Healthcare Decision-MakingFrom1 Mar 2023 → TodayFunding: IOF - technology validation in lab
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Feb 2023 → TodayFunding: BOF - projects
- Characterization of triggers of post-operative recurrence in Crohn’s disease in both the external and luminal side of the intestineFrom1 Jan 2023 → TodayFunding: FWO research project
- Development of a gut-on-a-chip model for pre-clinical testing of drugs for inflammatory bowel diseaseFrom12 Sep 2022 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseasesFrom15 Jun 2022 → TodayFunding: BOF - various
- Host-microbe interaction in intestinal homeostasis: unravelling the mechanisms involved in the onset of multiple inflammationrelated diseasesFrom1 Jan 2022 → TodayFunding: FWO EOS
- Histological healing in inflammatory bowel diseaseFrom1 Oct 2021 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
Publications
741 - 750 of 1016
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient(2013)
Authors: Niels Vande Casteele, Ann Gils, Paul Rutgeerts, Séverine Vermeire
Pages: 962 - 971 - Differentiation Between Etrolizumab (Rhumab Beta7) and Placebo in the Eucalyptus Phase II Randomized Double-Blind Placebo-Controlled Induction Study to Evaluate Efficacy and Safety in Patients With Refractory Moderate-to-Severely Active Ulcerative Colitis(2013)
Authors: Séverine Vermeire, Sharon O'Byrne, Marna Williams, John C Mansfield, Brian G Feagan, Julian Panes, Daniel C Baumgart, Stefan Schreiber, Iris Dotan, William Sandborn, et al.
Pages: S36 - S36 - Clinical and Molecular Characterization of Medically Refractory Acute, Severe Colitis: Preliminary Results From the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) Immunochip Study(2013)
Authors: Graham Radford-Smith, James D Doecke, Charlie W Lees, Dermot P McGovern, Séverine Vermeire, Limas Kupcinskas, Richard B Gearry, Johannes R Hov, Vibeke Andersen, Jean-Frederic Colombel, et al.
Pages: S470 - S470 - Clinical and Endocopic Improvement Following Hemopoietic Stem Cell Transplantation vs Mobilisation Alone in Crohn's Disease(2013)
Authors: Christopher J Hawkey, Matthieu Allez, Sandro Ardizzone, Liz Clark, Jean-Frederic Colombel, Silvio Danese, Dominique Farge-Bancel, Myriam Labopin, James O Lindsay, Anthony Norman, et al.
Pages: S21 - S22 - Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday(2013)
Authors: Filip J Baert, David Drobne, Vera Ballet, Ann Gils, Niels Vande Casteele, Scott Hauenstein, Sharat Singh, Steven Lockton, Paul Rutgeerts, Séverine Vermeire
Pages: S91 - S92 - Profile of pediatric Crohn's disease in Belgium(2013)
Authors: Ilse Hoffman, Séverine Vermeire, Kristel Van Steen
Pages: e588 - e598 - Genetic Associations With High-grade Dysplasia and Colorectal Cancer in Patients With Colonic Inflammatory Bowel Disease: Preliminary Results From Immunochip Using a Targeted Analytic Approach(2013)
Authors: Matti Waterman, Jo Knight, Joanne M Stempak, Krupa Krishnaprasad, Isabelle Cleynen, L Philip Schumm, Séverine Vermeire, Dermot P McGovern, Steven R Brant, Graham Radford-Smith, et al.
Pages: S148 - S148 - Letter: dry blood spots for anti-TNF treatment monitoring in IBD(2013)
Authors: Niels Vande Casteele, Paul Declerck, Marc Ferrante, Paul Rutgeerts, Séverine Vermeire, Ann Gils
Pages: 1024 - 1025 - Certolizumab pegol in the treatment of Crohn's disease(2013)
Authors: Marc Ferrante, Séverine Vermeire, Paul Rutgeerts
Pages: 595 - 605 - IBD in 2012: Pathogenesis and management of IBD--thinking outside the box(2013)
Authors: Séverine Vermeire, Paul Rutgeerts
Pages: 67 - 9
Patents
1 - 10 of 10
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- Predicting a treatment response in inflammatory bowel disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- Methods for predicting post-operative recurrence of crohn's disease (Inventor)
- A new inflammation associated, low cell count enterotype (Inventor)
- Biomarker test and method for assessing mucosal healing in response to treatment of ulcerative colitis (Inventor)
- Biomarker panel for assessment of mucosal healing (Inventor)
- METHODS FOR PREDICTING POST-OPERATIVE RECURRENCE OF CROHN'S DISEASE (Inventor)